Targeting the cell cycle as anticancer therapy has been actively investigated for decades, and recently, tremendous progress has been made as the highly selective CDK4/6 inhibitor palbociclib received FDA approval for breast cancer treatment. Here, CDK4 is linked to breast carcinoma.